CNS 2024 Conference Presentation: Diakonos Oncology’s Autologous Dendritic Cell Vaccine (DOC1021) Yields 93% 12-Month Survival for Glioblastoma Patients
October 1, 2024
Press Releases
Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance Its Highly Differentiated Dendritic Cell Vaccine (DOC1021) into a Phase 2 Clinical Trial
August 26, 2024
Diakonos Oncology Receives FDA Fast Track Designation for Pancreatic Cancer Dendritic Cell Vaccine; Names Daniel D. Von Hoff, M.D. to Scientific Advisory Board
July 15, 2024
Diakonos Oncology CFO Anthony Baldor to Provide Corporate Update at BIO International Convention In San Diego, June 3 – 6, 2024
June 3, 2024
Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma
April 9, 2024
Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer
February 26, 2024
Diakonos Oncology Names Paul Lammers, M.D., Veteran BioPharma Senior Executive, to its Board of Directors
February 20, 2024
Diakonos Receives FDA Orphan Drug Designation
January 2, 2024
Diakonos Completes Phase 1 GBM Recruitment
November 29, 2023
Ian H. Bellayr, Ph.D., Joins as Chief Regulatory Officer
November 17, 2023
Awarded TLSF Top 10 Most Promising Life Science Companies
November 8, 2023
Diakonos Awarded FDA Fast Track Designation
October 17, 2023